{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:46:01Z","timestamp":1790959561886,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.13588","type":"journal-article","created":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T15:21:25Z","timestamp":1653405685000},"page":"e2213588","source":"Crossref","is-referenced-by-count":30,"title":["Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016"],"prefix":"10.1001","volume":"5","author":[{"given":"Chan","family":"Shen","sequence":"first","affiliation":[{"name":"Division of Health Outcomes Research and Quality, Department of Surgery, Penn State College of Medicine, Hershey, Pennsylvania"},{"name":"Division of Health Services and Behavioral Research, Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Tannenbaum","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Health Sciences Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Horn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Health Sciences Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Rogers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Clinical Programs, the University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Eng","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouhao","family":"Zhou","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van","family":"Morris","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Overman","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Parseghian","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston"},{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A.","family":"Lopez-Olivo","sequence":"additional","affiliation":[{"name":"Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghav","family":"Kanwal","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee M.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Department of Colon and Rectal Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,5,24]]},"reference":[{"issue":"10207","key":"zoi220402r1","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","article-title":"Colorectal cancer.","volume":"394","author":"Dekker","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"zoi220402r2","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamaoncol.2015.1789","article-title":"Improved outcomes in metastatic colon cancer: giving credit where credit is due.","volume":"1","author":"Sargent","year":"2015","journal-title":"JAMA Oncol"},{"issue":"6","key":"zoi220402r3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrd.2017.70","article-title":"How much do clinical trials cost?","volume":"16","author":"Martin","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"zoi220402r4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/d41573-019-00074-z","article-title":"Trends in clinical success rates and therapeutic focus.","volume":"18","author":"Dowden","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"71","key":"zoi220402r6","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"7624","key":"zoi220402r7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"12","key":"zoi220402r8","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoto.2014.1570","article-title":"Unintended consequences of expensive cancer therapeutics\u2014the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture.","volume":"140","author":"Fojo","year":"2014","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"12","key":"zoi220402r9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.2013.53.8009","article-title":"American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes.","volume":"32","author":"Ellis","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi220402r12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1093\/annonc\/mdw538","article-title":"Do contemporary randomized controlled trials meet ESMO thresholds for meaningful clinical benefit?","volume":"28","author":"Del Paggio","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"zoi220402r13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/S0006-3495(89)82889-9","article-title":"Dynamics of a tightly coupled mechanism for flagellar rotation: bacterial motility, chemiosmotic coupling, protonmotive force.","volume":"55","author":"Meister","year":"1989","journal-title":"Biophys J"},{"issue":"23","key":"zoi220402r14","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer.","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"issue":"17","key":"zoi220402r15","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in braf v600e-mutated colorectal cancer.","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi220402r16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406).","volume":"39","author":"Kopetz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"26","key":"zoi220402r17","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency.","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi220402r18","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"zoi220402r19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer.","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi220402r20","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi220402r21","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial.","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"6","key":"zoi220402r22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"zoi220402r23","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival results and subgroup analyses from the BEACON Study.","volume":"39","author":"Tabernero","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi220402r24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.18203\/2349-3259.ijct20183748","article-title":"Challenges of conducting clinical trials in Asia.","volume":"5","author":"Ali","year":"2018","journal-title":"Int J Clin Trials"},{"issue":"3","key":"zoi220402r25","doi-asserted-by":"publisher","first-page":"121","DOI":"10.4103\/picr.PICR_109_18","article-title":"Clinical trials in Asia: a World Health Organization database study.","volume":"10","author":"Ali","year":"2019","journal-title":"Perspect Clin Res"},{"issue":"5","key":"zoi220402r26","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/hsc.2004.12.issue-5","article-title":"Why ethnic minority groups are under-represented in clinical trials: a review of the literature.","volume":"12","author":"Hussain-Gambles","year":"2004","journal-title":"Health Soc Care Community"},{"issue":"7401","key":"zoi220402r27","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/bmj.326.7401.1244","article-title":"Representation of South Asian people in randomised clinical trials: analysis of trials\u2019 data.","volume":"326","author":"Mason","year":"2003","journal-title":"BMJ"},{"issue":"10","key":"zoi220402r29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1200\/OP.20.00701","article-title":"Moving beyond the momentum: innovative approaches to clinical trial implementation.","volume":"17","author":"Eng","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"22","key":"zoi220402r30","doi-asserted-by":"publisher","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","article-title":"Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.","volume":"27","author":"Kopetz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi220402r31","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1177\/1740774506073105","article-title":"Cost-effectiveness as an outcome in randomized clinical trials.","volume":"3","author":"Hlatky","year":"2006","journal-title":"Clin Trials"},{"issue":"13","key":"zoi220402r32","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1002\/(ISSN)1097-0258","article-title":"Cost-effectiveness analysis for multinational clinical trials.","volume":"24","author":"Pinto","year":"2005","journal-title":"Stat Med"},{"issue":"2","key":"zoi220402r33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jval.2015.02.001","article-title":"Cost-effectiveness analysis alongside clinical trials II: an ISPOR Good Research Practices Task Force report.","volume":"18","author":"Ramsey","year":"2015","journal-title":"Value Health"},{"issue":"5","key":"zoi220402r34","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1001\/jamaoncol.2021.0379","article-title":"Evolution of the randomized clinical trial in the era of precision oncology.","volume":"7","author":"Del Paggio","year":"2021","journal-title":"JAMA Oncol"},{"issue":"10","key":"zoi220402r35","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1056\/NEJMra1601511","article-title":"The primary outcome is positive\u2014is that good enough?","volume":"375","author":"Pocock","year":"2016","journal-title":"N Engl J Med"},{"key":"zoi220402r5","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"zoi220402r10","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program: Incidence\u2014SEER 18 Regs Custom Data (with additional treatment fields). Nov 2018 Sub (1975-2016 varying). Accessed October 1, 2020. https:\/\/seer.cancer.gov\/data-software\/"},{"key":"zoi220402r11","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Accessed November 1, 2017. https:\/\/seer.cancer.gov\/"},{"key":"zoi220402r28","unstructured":"US Food and Drug Administration. FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND. Accessed August 21, 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/fda-acceptance-foreign-clinical-studies-not-conducted-under-ind-frequently-asked-questions"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2792599\/shen_2022_oi_220402_1652711409.95122.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,24]],"date-time":"2022-05-24T15:21:30Z","timestamp":1653405690000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2792599"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2022,5,24]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.13588","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,24]]}}}